HEALTHCARE INVESTMENTS
DERMATOLOGY
ARKIN DERMA
Arkin Derma is specifically focused on investments for developments of technologies and products in dermatology. The leading company in this investment arm is Sol-Gel.
Sol-Gel
Sol-Gel is a clinical-stage pharmaceuticals company that develops a diverse line of innovative and generic products. Through its proprietary silica-based microencapsulation technology, Sol-Gel offers more effective treatments for a variety of skin diseases, with better tolerated medications.
Despite the fact that dermatological conditions have a profound effect on patient quality of life - there are few innovations in this field. Via Sol-gel, Arkin Derma aims to find and expose these innovations that can make the difference.
DR. ALON SERI-LEVY - CEO
Dr. Alon Seri-Levy has headed Sol-Gel since its inception in 1997. Prior to founding Sol-Gel, he established the Computer-Aided Drug Design department at Peptor Ltd. He holds a Ph.D. summa cum laude, in Chemistry, from The Hebrew University of Jerusalem and completed post-doctorate studies at Oxford University.
